Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Gross Profit (2016 - 2025)

Protalix BioTherapeutics has reported Gross Profit over the past 16 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Gross Profit at $4.5 million for Q4 2025, down 68.58% from a year ago — trailing twelve months through Dec 2025 was $25.8 million (down 11.45% YoY), and the annual figure for FY2025 was $25.8 million, down 11.45%.
  • Gross Profit for Q4 2025 was $4.5 million at Protalix BioTherapeutics, down from $9.5 million in the prior quarter.
  • Over the last five years, Gross Profit for PLX hit a ceiling of $28.9 million in Q2 2023 and a floor of $1.1 million in Q1 2024.
  • Median Gross Profit over the past 5 years was $6.4 million (2022), compared with a mean of $7.4 million.
  • Peak annual rise in Gross Profit hit 779.26% in 2024, while the deepest fall reached 86.11% in 2024.
  • Protalix BioTherapeutics' Gross Profit stood at $5.4 million in 2021, then grew by 15.16% to $6.2 million in 2022, then plummeted by 73.79% to $1.6 million in 2023, then skyrocketed by 779.26% to $14.3 million in 2024, then crashed by 68.58% to $4.5 million in 2025.
  • The last three reported values for Gross Profit were $4.5 million (Q4 2025), $9.5 million (Q3 2025), and $9.8 million (Q2 2025) per Business Quant data.